undamentalytics Newsletter
Sign in

Grail, Inc. (GRAL) stock

Add to watchlist

Add holding +

NASDAQ: GRAL Nasdaq Life Sciences Tools & Services Next results ~November 4, 2026

D Fundamentals grade

Grail, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Grail, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Grail, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 4 selling0 purchases and 47 sales by directors and officers, last 12 monthsInsider trades
  • Funds176 adding, 147 cuttingOf 44 active managers that changed their stake, 22 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Grail files

Where Grail stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $165m, up 23.1% on a year earlier, faster than the 19.4% growth a quarter earlier. That growth ranks 2 of 31 among the life sciences tools & services companies we cover. Free-cash-flow margin rose to -179.2% from -276.8% a year earlier. Operating margin widened to -338.4% from -471.3%. The diluted share count is up 18.5% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 2 financial-health checks.

Our model value for Grail is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Grail, Inc.'s trailing-twelve-month revenue grew 23.1% year on year, with a free-cash-flow margin of -179.2%. Where it stands out: revenue growth of 23.1% ranks 7 of 54 life sciences tools & services companies we cover. Where it lags: stock pay as % of revenue of 38.9% ranks 49 of 53 life sciences tools & services companies we cover.

Current signal Operating margin expanding: TTM operating margin reached -338.4%, up 132.9pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 23.1% over the last 12 months, against a median of 6.9% for life sciences tools & services companies we cover.
  • Growth speeding up. The growth rate is 3.6 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 132.9 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Loss-making. Operating margin is -338.4%: costs exceed revenue.
  • Burning cash. Free cash flow was -179.2% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 38.9% of revenue, against a median of 4.4% for life sciences tools & services companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 18.5% in a year.
  • High sales multiple. The shares trade at 32 times revenue while operating margins remain thin.
  • Volatile shares. Over the past year the shares showed annualised volatility of 102% and a beta of 3.0 against the S&P 500.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$1.34 against an average estimate of -$2.43: beat by 44.9%
Revenue
$45m, up 25.7% on a year earlier
Share reaction
-12.8% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 4, 2026; average EPS estimate -$1.90

Grail's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-6.7%
  • 1 week-4.4%
  • 1 month-6.6%
  • This year+56.3%
  • 1 year+45.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$165M
Operating margin
-338.4%
Net margin
-236.9%
EPS (TTM, diluted)
$-9.75

Growth

Revenue growth
+23.1%
Change in growth rate
+3.6 pts
Share count change
+18.5%

Cash

Free cash flow (TTM)
-$296M
FCF margin
-179.2%
Stock pay % of revenue
38.9%

Earnings

Last results
August 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Insider trade
  3. Insider trade
  4. Insider trade
  5. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Grail, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Grail, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.3%: the 10-year Treasury yield (4.9%) plus a beta of 1.41 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$15 ~$13–$16 Left out: out of range vs price (0.11x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$15 ~$12–$35 Left out: out of range vs price (0.11x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Grail, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20242025Now
Share price$17.85$85.59$133.76
Market value$569m$3.1bn$5.4bn
+ Net debt (− = net cash)−$214m−$250m−$56m
Enterprise value$355m$2.9bn$5.3bn
Multiples
Price / sales 4.5x21.4x32.5x
Price / earnings ———
Price / free cash flow ———
EV / EBITDA ———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $44m and EPS of −$1.90 (range −$2.85 to −$1.49) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$7.52 +36% $181m +23%
Next −$8.25 −10% $227m +26%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −17.8% on 90 days ago. In the last 30 days, 1 analyst raised Grail, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Grail, Inc., last 90 days
−$10.00 −$5.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$9.14 Current fiscal year, 60 days ago: −$7.67 Current fiscal year, 30 days ago: −$7.52 Current fiscal year, 7 days ago: −$7.52 Current fiscal year, Now: −$7.52 −$7.52 Next fiscal year, 90 days ago: −$9.72 Next fiscal year, 60 days ago: −$9.87 Next fiscal year, 30 days ago: −$8.92 Next fiscal year, 7 days ago: −$8.25 Next fiscal year, Now: −$8.25 −$8.25

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$9.14−$9.72
60 days ago −$7.67−$9.87
30 days ago −$7.52−$8.92
7 days ago −$7.52−$8.25
Now −$7.52−$8.25

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$2.43 −$1.34 +44.9%
Mar 2026 −$1.96 −$1.37 +30.1%
Dec 2025 −$2.53 −$2.44 +3.6%
Sept 2025 −$3.27 −$2.46 +24.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026

No numeric guidance in Grail, Inc.'s latest earnings release (filed August 5, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

10 analysts, Oct 2026
Buy550%
Hold550%
Sell00%

Monthly trend

  1. Oct 20265510
  2. Sep 20265611
  3. Aug 2026459
  4. Jul 2026459

Counts of recommendations published by analysts covering Grail, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
18.6%
of tradable shares
Days to cover
5.44
at average volume
Short interest, 1 month
−5%
to October 15, 2026
Held by institutions
87%
of shares
Held by insiders
4.8%
of shares
Employees
910
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +45.5%

$91.93 on October 31, 2025 to $133.76

ThenNowEffect
Revenue (last 12 months) $134m $165m +23.1%
P/S multiple 23.2x 32.5x +40.1%
Share count 34m 40m −15.6%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20252026 to date
Return
GRAL+380%+56%
Industry peers (median)−7%+15%
S&P 500+18%+11%
Months that ended higher
GRAL67%64%
S&P 50075%46%
Largest fall from a high during the year
GRAL−61%−63%
S&P 500−19%−9%

Worst fall since June 12, 2024: 63% from January 22, 2026 to February 23, 2026. Getting back needed a 170% gain, reached on September 24, 2026, 213 days after the low.

Price behaviour

52-week range
$43.03 – $158.92
From 52-week high
−15.8%
vs 50-day average
+18.3%
vs 200-day average
+71.0%
Volatility (1 year)
102%
Beta vs S&P 500
3.02

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±10.4%
After a week
7 up, 5 down
typical move ±13.8%
After a month
9 up, 3 down
typical move ±35.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −12.8% −0.4% −5.2% +10.9%
May 5, 2026 +12.7% +2.2% +11.4% +19.6%
February 19, 2026 −50.9% +0.5% −43.2% −54.2%
January 12, 2026 +1.9% 0.0% +1.2% +0.3%
November 12, 2025 −0.2% −1.6% +5.5% +8.9%
October 16, 2025 +3.3% −0.1% +9.4% +5.4%
August 12, 2025 +3.9% +1.4% −3.9% +18.2%
May 13, 2025 −8.6% +0.8% +9.3% +16.5%
February 20, 2025 −22.6% −2.1% −25.3% −42.4%
January 15, 2025 −3.8% +1.6% +43.5% +204.0%
November 12, 2024 +4.1% −0.3% −3.3% +35.8%
August 13, 2024 +0.1% +2.0% +4.5% −11.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Grail, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Grail, Inc.
$100M $120M $140M $160M $180M FY24 Q1 FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q2 Revenue (TTM), FY24 Q1: $100.2M Revenue (TTM), FY24 Q2: $109.7M Revenue (TTM), FY24 Q3: $117.7M Revenue (TTM), FY24 Q4: $125.6M Revenue (TTM), FY25 Q1: $130.7M Revenue (TTM), FY25 Q2: $134.3M Revenue (TTM), FY25 Q3: $141.8M Revenue (TTM), FY25 Q4: $147.2M Revenue (TTM), FY26 Q1: $156.1M Revenue (TTM), FY26 Q2: $165.3M $165.3M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q1 $100.2M
FY24 Q2 $109.7M
FY24 Q3 $117.7M
FY24 Q4 $125.6M
FY25 Q1 $130.7M
FY25 Q2 $134.3M
FY25 Q3 $141.8M
FY25 Q4 $147.2M
FY26 Q1 $156.1M
FY26 Q2 $165.3M
Revenue growth, TTM YoY Grail, Inc.
15% 20% 25% 30% 35% FY25 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 FY26 Q2 Revenue growth, TTM YoY, FY25 Q1: 30.5% Revenue growth, TTM YoY, FY25 Q2: 22.4% Revenue growth, TTM YoY, FY25 Q3: 20.5% Revenue growth, TTM YoY, FY25 Q4: 17.2% Revenue growth, TTM YoY, FY26 Q1: 19.4% Revenue growth, TTM YoY, FY26 Q2: 23.1% 23.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY25 Q1 30.5%
FY25 Q2 22.4%
FY25 Q3 20.5%
FY25 Q4 17.2%
FY26 Q1 19.4%
FY26 Q2 23.1%
Operating margin (TTM) Grail, Inc.
-3000% -2000% -1000% 0% FY24 Q1 FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q2 Operating margin (TTM), FY24 Q1: -1536.0% Operating margin (TTM), FY24 Q2: -2711.6% Operating margin (TTM), FY24 Q3: -1909.4% Operating margin (TTM), FY24 Q4: -1743.0% Operating margin (TTM), FY25 Q1: -1618.3% Operating margin (TTM), FY25 Q2: -471.3% Operating margin (TTM), FY25 Q3: -405.2% Operating margin (TTM), FY25 Q4: -382.0% Operating margin (TTM), FY26 Q1: -348.7% Operating margin (TTM), FY26 Q2: -338.4% -338.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q1 -1536.0%
FY24 Q2 -2711.6%
FY24 Q3 -1909.4%
FY24 Q4 -1743.0%
FY25 Q1 -1618.3%
FY25 Q2 -471.3%
FY25 Q3 -405.2%
FY25 Q4 -382.0%
FY26 Q1 -348.7%
FY26 Q2 -338.4%
FCF margin (TTM) Grail, Inc.
-600% -400% -200% 0% FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 FCF margin (TTM), FY24 Q4: -463.7% FCF margin (TTM), FY25 Q1: -357.7% FCF margin (TTM), FY25 Q2: -276.8% FCF margin (TTM), FY25 Q3: -232.6% FCF margin (TTM), FY25 Q4: -203.8% FCF margin (TTM), FY26 Q1: -187.2% FCF margin (TTM), FY26 Q2: -179.2% -179.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q4 -463.7%
FY25 Q1 -357.7%
FY25 Q2 -276.8%
FY25 Q3 -232.6%
FY25 Q4 -203.8%
FY26 Q1 -187.2%
FY26 Q2 -179.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Jan 2023 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 56 93 126 147 165
EBITDA −5,426 −1,495 −2,169 −544 −542
Operating income −5,443 −1,515 −2,189 −562 −559
Net income −5,399 −1,466 −2,027 −408 −392
Diluted EPS −$173.89 −$47.21 −$63.54 −$11.11 −$9.75
Growth (year on year)
Revenue — +67.6% +34.9% +17.2% +23.1%
Margins
EBITDA margin <−999% <−999% <−999% −369.7% −328.1%
Operating margin <−999% <−999% <−999% −382.0% −338.4%
Net margin <−999% <−999% <−999% −277.5% −236.9%
Free-cash-flow margin <−999% −653.8% −463.7% −203.8% −179.2%
Cash flow
Cash from operations −561 −596 −577 −299 −295
Capital spending 23 13 5 1 1
Free cash flow −584 −609 −582 −300 −296
Stock-based pay 76 97 86 58 64
Free cash flow after stock pay −660 −706 −668 −358 −360
Balance sheet
Cash 242 97 214 250 56
Total debt 0 0 0 0 0
Net debt (negative = net cash) −242 −97 −214 −250 −56
Diluted shares 31m 31m 32m 37m 40m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $2.8bn
Short-term assets $915mLonger-term assets $1.9bn
What it owes, and who funded it · $2.8bn
Short-term liabilities $84mLonger-term liabilities $217mShareholders' equity $2.5bn
  • Short-term assets cover short-term liabilities $915m of assets due within a year against $84m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $915m short-term assets against $217m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Grail, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+18.5%
year over year
R&D spending
115.6%
of revenue
Days sales outstanding
44 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated GRAL PACB QTRX CYRX CTKB MRVI Median
Revenue, last 12 months $165m $159m $153m $186m $207m $209m $229m
Revenue growth, last 12 months 23.1% 2.0% 22.0% 12.1% 5.4% −5.0% 6.9%
Revenue growth, 3-year average — 2.9% 11.1% −8.2% 5.6% −27.3% 2.9%
Revenue growth, latest quarter 25.7% −1.9% 34.4% 7.7% 5.6% 8.5% 8.5%
Gross margin — 36.4% 42.7% 47.1% 53.2% 34.9% 51.9%
Operating margin −338.4% −83.5% −99.6% −21.2% −21.6% −56.1% −14.3%
Operating margin, 3-year average <−999% −250.8% −70.6% −60.1% −16.1% −73.7% −22.4%
Net margin −236.9% −82.5% −80.2% −20.1% −39.0% −37.1% −16.1%
Cash from operations / revenue −178.4% −74.1% −52.7% 4.3% −2.9% −12.1% 1.3%
Free-cash-flow margin −179.2% −77.5% −53.2% −10.8% −5.9% −17.2% −2.2%
Free-cash-flow margin, 3-year average — −104.4% −36.8% −22.6% 1.7% −14.3% 0.6%
Stock pay / revenue 38.9% 21.5% 12.1% 5.2% 10.3% 14.3% 4.4%
Change in share count 18.5% 0.9% 21.0% 0.6% −0.3% 2.3% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 23.1% 6.9% 7 of 54
Change in growth rate Growth +3.6pp +0.4pp 12 of 54
Operating margin Profitability -338.4% -14.3% 47 of 52
Net margin Profitability -236.9% -12.2% 49 of 54
Free-cash-flow margin Cash generation -179.2% -1.3% 49 of 54
Stock pay as % of revenue Cash generation 38.9% 4.4% 49 of 53
Change in share count Balance sheet 18.5% 1.0% 39 of 46
Days sales outstanding Balance sheet 44 days 62 days 9 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Screening Revenue $139M 94.2% ▲ 27.6%
Developmental Services Revenue $8.6M 5.8% ▼ 49.5%

From Grail, Inc.'s 10-K filed March 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2.7B
Institutions reporting
371
Shares held vs prior quarter
▲ 11.1%
Positions opened / closed
58 / 49

Top buyers and sellers, Q2 2026: 176 institutions bought and 147 sold ; the biggest buyer was Arbiter Partners Capital Management LLC (+1.0M shares) and the biggest seller Alyeska Investment Group, L.P (−540K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Farallon Capital Management, L.L.C. $284M 4.2M 10.6% ▲ 27.9%
Baker Bros. Advisors LP $275M 4.0M 10.3% 0.0%
Blackrock, Inc. $244M 3.6M 9.2% ▲ 20.5%
State Street Corp $163M 2.4M 6.1% ▲ 26.1%
Primecap Management Co $149M 2.2M 5.6% ▲ 18.2%
Arbiter Partners Capital Management LLC $141M 2.1M 5.3% ▲ 99.9%
Sessa Capital Im, L.P. $139M 2.0M 5.2% ▲ 18.5%
Deep Track Capital, LP $125M 1.8M 4.7% ▲ 6.5%
Vanguard Capital Management LLC $112M 1.6M 4.2% ▲ 7.5%
Morgan Stanley $99.8M 1.5M 3.7% ▼ 10.4%
Geode Capital Management, LLC $67.7M 991K 2.5% ▲ 19.7%
Goldman Sachs Group Inc $51.1M 748K 1.9% ▲ 28.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Grail, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $38.1M 47 trades by 4 insiders · 27% under pre-set plans
Net ▼ $38.1M net selling
Insider Date Trade Shares Price Value
Ofman Joshua J. Chief Executive Officer October 15, 2026 Sell pre-set plan 2,114 $138.79 $293,394
Ofman Joshua J. Chief Executive Officer October 15, 2026 Sell pre-set plan 6,034 $137.63 $830,465
Ofman Joshua J. Chief Executive Officer October 15, 2026 Sell pre-set plan 7,052 $136.83 $964,946
Ofman Joshua J. Chief Executive Officer October 15, 2026 Sell pre-set plan 3,400 $135.44 $460,508
Ofman Joshua J. Chief Executive Officer October 15, 2026 Sell pre-set plan 1,000 $134.38 $134,384
Ofman Joshua J. Chief Executive Officer October 15, 2026 Sell pre-set plan 400 $133.12 $53,247
Freidin Aaron Chief Financial Officer October 5, 2026 Sell 23,619 $146.39 $3.5M
Partridge Andrew John Chief Growth Officer October 5, 2026 Sell 7,873 $146.39 $1.2M
Ofman Joshua J. Chief Executive Officer September 21, 2026 Sell pre-set plan 37,752 $94.98 $3.6M
Ofman Joshua J. Chief Executive Officer September 21, 2026 Sell pre-set plan 2,125 $92.32 $196,180
Ofman Joshua J. Chief Executive Officer September 21, 2026 Sell pre-set plan 1,454 $93.61 $136,109
Ofman Joshua J. Chief Executive Officer September 21, 2026 Sell pre-set plan 6,200 $96.43 $597,866

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 14, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 5, 2026
  • February 19, 2026
  • January 12, 2026
  • November 12, 2025
  • October 16, 2025

Recent SEC filings

Data status

When each part of this page on Grail, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Grail, Inc. in brief

What does Grail, Inc. do?
Grail, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Grail, Inc.'s stock ticker?
Grail, Inc. trades under the ticker GRAL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Grail, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Grail, Inc. reported revenue of $165M, 23.1% higher than a year earlier, according to its SEC filings.
What is Grail, Inc.'s free cash flow?
Grail, Inc.'s free-cash-flow margin is -179.2% of revenue over the trailing twelve months, ranking 49 of the 54 life sciences tools & services companies we cover.
Who are Grail, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Farallon Capital Management, L.L.C., Baker Bros. Advisors LP and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Grail, Inc.'s market cap?
On November 2, 2026, Grail, Inc.'s market capitalisation was about $5.4B and net debt of -$55.6M. Market figures come from third-party market data and may be delayed.
Who are Grail, Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Grail, Inc. are Pacific Biosciences Of California, Inc., Quanterix Corp, Cryoport, Inc., Cytek Biosciences, Inc. and Maravai Lifesciences Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Grail, Inc.'s.
Are insiders buying or selling Grail, Inc. stock?
Over the last 12 months, Grail, Inc.'s directors and officers reported 0 open-market purchases and 47 sales on Form 4. The insider trading page charts every trade.
When is Grail, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Grail, Inc. announces its own schedule.